Search Results - "Breitkreutz, I."

Lenalidomide inhibits osteoclastogenesis, survival factors and bone-remodeling markers in multiple myeloma by Breitkreutz, I, Raab, M S, Vallet, S, Hideshima, T, Raje, N, Mitsiades, C, Chauhan, D, Okawa, Y, Munshi, N C, Richardson, P G, Anderson, K C

“…Osteolytic bone disease in multiple myeloma (MM) is caused by enhanced osteoclast (OCL) activation and inhibition of osteoblast function. Lenalidomide and…”
Get full text

Bortezomib improves outcome after SCT in multiple myeloma patients with end-stage renal failure by Breitkreutz, I, Heiss, C, Perne, A, Beimler, J, Jäger, D, Egerer, G, Ho, A D, Neben, K, Zeier, M, Goldschmidt, H, Raab, M S

“…Patients with multiple myeloma and dialysis-dependent renal failure have dismal outcomes. In this retrospective analysis of a case series, we evaluated 27…”
Get full text

Thalidomide in newly diagnosed multiple myeloma: influence of thalidomide treatment on peripheral blood stem cell collection yield by BREITKREUTZ, I, LOKHORST, H. M, SALWENDER, H, HAENE, A, SONNEVELD, P, COLDSCHMIDT, H, RAAB, M. S, VAN DER HOLT, B, CREMER, F. W, HERRMANN, D, GLASMACHER, A, SCHMIDT-WOLF, I. G. H, BLAU, I. W, MARTIN, H

“…In a phase III randomized, multicenter study, the German-speaking Myeloma-Multicenter Group (GMMG) and the Dutch-Belgian Hemato-Oncology Cooperative Group…”
Get full text

Targeted treatments to improve stem cell outcome: old and new drugs by Raab, M S, Breitkreutz, I, Anderson, K C

“…Thalidomide, lenalidomide and bortezomib have been approved for the treatment of relapsed or refractory multiple myeloma in the recent years. These agents are…”
Get full text

Lenalidomide inhibits osteoclastogenesis, survival factors and bone-remodeling markers in multiple myeloma by Okawa, Y, Munshi, N.C, Raje, N, Anderson, K.C, Breitkreutz, I, Chauhan, D, Vallet, S, Raab, M.S, Mitsiades, C, Hideshima, T, Richardson, P.G

Get full text

Molecular monitoring of tumour load kinetics predicts disease progression after non-myeloablative allogeneic stem cell transplantation in multiple myeloma by Raab, M. S., Cremer, F. W., Breitkreutz, I. N., Gerull, S., Luft, T., Benner, A., Goerner, M., Ho, A. D., Goldschmidt, H., Moos, M.

“…Background: Non-myeloablative allogeneic stem cell transplantation followed by immunomodulatory therapies is considered a potentially curative approach in the…”
Get full text

Joint HOVON-50/GMMG-HD3 randomized trial on the effect of thalidomide as part of a high-dose therapy regimen and as maintenance treatment for newly diagnosed myeloma patients by GOLDSCHMIDT, H, SONNEVELD, P, HOELZER, D, HO, A. D, LOKHORST, H. M, CREMER, F. W, VAN DER HOLT, B, WESTVEER, P, BREITKREUTZ, I, BENNER, A, GLASMACHER, A, SCHMIDT-WOLF, I. G. D, MARTIN, H

Get full text

Thalidomide in induction treatment increases the very good partial response rate before and after high-dose therapy in previously untreated multiple myeloma by Lokhorst, Henk M, Schmidt-Wolf, Ingo, Sonneveld, Pieter, van der Holt, Bronno, Martin, Hans, Barge, Rene, Bertsch, Uta, Schlenzka, Jana, Bos, Gerard M.J, Croockewit, Sandra, Zweegman, Sonja, Breitkreutz, Iris, Joosten, Peter, Scheid, Christof, van Marwijk-Kooy, Marinus, Salwender, Hans-Juergen, van Oers, Marinus H.J, Schaafsma, Ron, Naumann, Ralph, Sinnige, Harm, Blau, Igor, Delforge, Michel, de Weerdt, Okke, Wijermans, Pierre, Wittebol, Shulamiet, Duersen, Ulrich, Vellenga, Edo, Goldschmidt, Hartmut, for Dutch-Belgian HOVON and German GMMG

“…1 Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON), The Netherlands and 2 German GMMG Correspondence: H.M. Lokhorst, Dept. of Hematology, University…”
Get full text

A Predictive Score for Early Mortality during Induction Therapy in Newly Diagnosed Transplant-Eligible Multiple Myeloma - an Analysis from Five GMMG and HOVON Multicenter Phase III Trials by Mai, Elias K, Hielscher, Thomas, Bertsch, Uta, Schlenzka, Jana, Salwender, Hans Jürgen, Lokhorst, Henk M, Munder, Markus, van der Holt, Bronno, Gerecke, Christian, Pfreundschuh, Michael, Duhrsen, Ulrich, Brossart, Peter, Zweegman, Sonja, Neben, Kai, Hillengass, Jens, Raab, Marc-Steffen S, Hose, Dirk, Vellenga, Edo, Merz, Maximilian, Breitkreutz, Iris, Jauch, Anna, Kersten, Marie José, Martin, Hans, Lindemann, Hans-Walter, Peter, Norma, Croockewit, Sandra, Blau, Igor Wolfgang, Scheid, Christof, Weisel, Katja C., Sonneveld, Pieter, Goldschmidt, Hartmut

“…Introduction: Early mortality is up to 10% in newly diagnosed multiple myeloma (MM) with no improvement in subsequent study generations until 2002 (Augustson…”
Get full text

Prevention of venous thromboembolism with low molecular-weight heparin in patients with multiple myeloma treated with thalidomide and chemotherapy by Minnema, M C, Breitkreutz, I, Auwerda, J J A, van der Holt, B, Cremer, F W, van Marion, A M W, Westveer, P H M, Sonneveld, P, Goldschmidt, H, Lokhorst, H M

Get full text

Targeted treatments to improve stem cell outcome : old and new drugs: Myeloma by RAAB, M. S, BREITKREUTZ, I, ANDERSON, K. C

Get full text

The outcome of autologous stem cell transplantation in patients with plasma cell disorders and dialysis-dependent renal failure by Raab, MS, Breitkreutz, I, Hundemer, M, Benner, A, Klaus, J, Hegenbart, U, Moehler, T, Ho, AD, Zeier, M, Goldschmidt, H

“…Department of Internal Medicine V, University of Heidelberg, Germany. Marc_Raab@dfci.harvard.edu Patients with multiple myeloma and end-stage renal failure on…”
Get full text

Erratum: Lenalidomide inhibits osteoclastogenesis, survival factors and bone-remodeling markers in multiple myeloma by Breitkreutz, I, Raab, M S, Vallet, S, Hideshima, T, Raje, N, Mitsiades, C, Chauhan, D, Okawa, Y, Munshi, N C, Richardson, P G, Anderson, K C

“…Correction to: Leukemia (2008) 22, 1925–1932; doi:10.1038/leu.2008.174; published online 3 July 2008 Owing to a typesetting error, Figure 2b of the above…”
Get full text

Lenalidomide and bortezomib induce osteoclast cytotoxicity and decrease BAFF secretion in osteoclasts in human multiple myeloma: Clinical implications by Breitkreutz, I., Tai, Y., Li, X., Coffey, R., Raab, M. S., Song, W., Hideshima, T., Chauhan, D., Munshi, N., Anderson, K. C.

“…Abstract only 7606 Background: Myeloma bone disease is caused by an enhanced osteoclast (OCL) activation, leading to osteolytic bone lesions. OCL have recently…”
Get full text

First-line treatment of multiple myeloma by Breitkreutz, I, Raab, M, Goldschmidt, H

“…Within the last two decades the therapeutic options for newly diagnosed multiple myeloma have changed dramatically. The implementation of high-dose…”
Get full text

High dose of Zoledronic acid inhibits both osteoclasts and osteoblasts in an In Vivo mouse model by Pozzi, Samantha, Hideshima, Teru, Vallet, Sonia, Mukherjee, Siddhartha, Chhetri, Shweta, Cirstea, Diana, Vaghela, Nileshwari, Thomas, Clare, Rosa, Dilani, Rosen, Eyal, Ikeda, Hiroshi, Okawa, Yutaka, Breitkreutz, Iris, Kiziltepe, Tanyel, Santo, Loredana, Schoonmaker, Jesse, Schipani, Ernestina, Bouxsein, Mary L, Anderson, Kenneth C, Raje, Noopur S

Get full text

Erratum zu: Primärtherapie beim Multiplen Myelom by Breitkreutz, I., Raab, M., Goldschmidt, H.

“…Erratum zu: Internist 2018 https://doi.org/10.1007/s00108-018-0527-x Im Originalbeitrag ist Tab. 2 fehlerhaft. Die Fehler betreffen die Spalte…”
Get full text

Primärtherapie beim Multiplen Myelom by Breitkreutz, I., Raab, M., Goldschmidt, H.

“…Zusammenfassung Die Therapielandschaft des neu diagnostizierten multiplen Myeloms hat sich im Verlauf der letzten beiden Jahrzehnte entscheidend verändert. Die…”
Get full text

Erratum to: First-line treatment of multiple myeloma by Breitkreutz, I, Raab, M, Goldschmidt, H

Get full text

First-line treatment of multiple myeloma by Breitkreutz, I, Raab, M, Goldschmidt, H

Get full text